LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

Search

Smith & Nephew PLC ADR

Открыт

35.23 -0.62

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

34.83

Макс.

35.27

Ключевые показатели

By Trading Economics

Доход

296M

Продажи

3B

P/E

Средняя по отрасли

31.586

121.746

Дивидендная доходность

2.17

Рентабельность продаж

9.895

Сотрудники

17,000

EBITDA

723M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

-1.71% downside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

2.17%

2.26%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

15B

Предыдущая цена открытия

35.85

Предыдущая цена закрытия

35.23

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Smith & Nephew PLC ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 февр. 2026 г., 23:26 UTC

Главные движущие силы рынка

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 февр. 2026 г., 22:31 UTC

Отчет

Correction to America Movil 4Q Profit Article

10 февр. 2026 г., 22:22 UTC

Отчет

America Movil 4Q Profit Jumps on Lower Financial Costs

10 февр. 2026 г., 23:51 UTC

Обсуждения рынка
Отчет

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 февр. 2026 г., 23:42 UTC

Обсуждения рынка

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 февр. 2026 г., 23:40 UTC

Обсуждения рынка
Отчет

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 февр. 2026 г., 23:21 UTC

Обсуждения рынка

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 февр. 2026 г., 23:21 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

10 февр. 2026 г., 22:17 UTC

Обсуждения рынка

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 февр. 2026 г., 22:15 UTC

Отчет

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 февр. 2026 г., 22:10 UTC

Отчет

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 февр. 2026 г., 22:10 UTC

Отчет

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 февр. 2026 г., 22:09 UTC

Отчет

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 февр. 2026 г., 22:09 UTC

Отчет

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 февр. 2026 г., 22:01 UTC

Отчет

Intact Financial 4Q EPS C$5.24 >IFC.T

10 февр. 2026 г., 21:54 UTC

Отчет

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 февр. 2026 г., 21:53 UTC

Отчет

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 февр. 2026 г., 21:51 UTC

Отчет

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 февр. 2026 г., 21:51 UTC

Отчет

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 февр. 2026 г., 21:51 UTC

Отчет

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 февр. 2026 г., 21:51 UTC

Отчет

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 февр. 2026 г., 21:51 UTC

Отчет
Приобретения, слияния, поглощения

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 февр. 2026 г., 21:50 UTC

Отчет
Приобретения, слияния, поглощения

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 февр. 2026 г., 21:50 UTC

Отчет

James Hardie Industries 3Q EPS 12c >JHX

10 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

10 февр. 2026 г., 21:50 UTC

Отчет

James Hardie Industries 3Q Adj EPS 24c >JHX

10 февр. 2026 г., 21:49 UTC

Отчет

James Hardie Industries 3Q Sales $1.24B >JHX

10 февр. 2026 г., 21:49 UTC

Отчет
Приобретения, слияния, поглощения

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 февр. 2026 г., 21:48 UTC

Отчет
Приобретения, слияния, поглощения

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 февр. 2026 г., 21:47 UTC

Отчет
Приобретения, слияния, поглощения

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Сравнение c конкурентами

Изменение цены

Smith & Nephew PLC ADR Прогноз

Целевая цена

By TipRanks

-1.71% падение

Прогноз на 12 месяцев

Средняя 34.46 USD  -1.71%

Максимум 34.91 USD

Минимум 34 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Smith & Nephew PLC ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

2 ratings

0

Покупка

2

Удержание

0

Продажа

Техническая оценка

By Trading Central

26.64 / 28.37Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat